General Information of DT
DT ID DTD0461
Gene Name SLC6A9
Protein Name Sodium- and chloride-dependent glycine transporter 1
Gene ID
6536
UniProt ID
P48067
TCDB ID
2.A.22.2.12
3D Structure

Modelled DT Structure

Method: homology modeling

Template PDB: 4XPT_A

Identity: 44.803%

Minimized Score: -1450.84 kcal/mol

Detail: Structure Info

Synonyms GCENSG; GlyT-1; GlyT1; SLC6A9; Solute carrier family 6 member 9
DT Family Neurotransmitter:Sodium Symporter (NSS) Family ;
Tissue Specificity Isoform GlyT-1A and isoform GlyT-1B can befound in brain, kidney, pancreas, lung, placenta and liver butisoform GlyT-1C is only found in brain.
Function This transporter can terminate the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals and may play a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission.
Endogenous Substrate(s) Cl-; Na+
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT

(γ) Transcriptional Regulation of This DT

(δ) Epigenetic Regulation of This DT

(ε) Exogenous Modulation of This DT

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences

(γ) Outward/inward-facing Conformation

(δ) Xenobiotics-regulated Structural Variability

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT

(γ) Species- and Tissue-specific DT Abundances

Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Glycine
Approved Drug Info Dietary shortage 5B7Z [1]

 Clinical Trial Drug

Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Sarcosine
Phase 2 Drug Info Schizophrenia 6A20 [2]
References
1 Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans. Hum Genet. 2016 Nov;135(11):1263-1268.
2 Glycine is taken up through GLYT1 and GLYT2 transporters into mouse spinal cord axon terminals and causes vesicular and carrier-mediated release of its proposed co-transmitter GABA. J Neurochem. 2001 Mar;76(6):1823-32.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.